Abstract | Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modelling, drug discovery and cell therapy development. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clinical trial using human iPSC-derived products has been initiated. In particular, the combination of human iPSC technology with recent developments in gene editing and 3D organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine. In this Review, we discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.
In 2006, a major technological breakthrough in science and medicine was made with the report that cells with a gene expression profile and developmental potential similar to embryonic stem cells (ESCs) can be generated from mouse somatic cells (such as fibroblasts) by using a cocktail of four transcription factors 1 . These cells were termed induced pluripotent stem cells (iPSCs), and the four factors -OCT4, SOX2, KLF4 and MYC -were named "Yamanaka factors". Just 1 year later, two research groups independently reported the generation of iPSCs from human fibroblasts 2, 3 . Human iPSC technology, which has evolved rapidly since 2007
, has ushered in an exciting new era for the fields of stem cell biology and regenerative medicine, as well as the fields of disease modelling and drug discovery. Soon after the development of the technology, human iPSCs were rapidly applied to generate human 'disease in a dish' models and used for drug screening for both efficacy and potential toxicities. Such approaches are now becoming increasingly popular given the surge in interest in phenotypic screening and the advantages of human iPSCs in disease modelling compared with traditional cellular screens. These advantages include their human origin, easy accessibility, expandability, ability to give rise to almost any cell types desired, avoidance of ethical concerns associated with human ESCs, and the potential to develop personalized medicine using patient-specific iPSCs. Furthermore, recent advances in gene editing technologies -in particular, the CRISPR-Cas9 technology -are enabling the rapid generation of genetically defined human iPSC-based disease models. iPSCs are also a key component of an emerging generation of more physiologically representative cellular platforms incorporating 3D architectures and multiple cell types.
iPSC technology has also attracted considerable interest in its potential applicability for regenerative medicine. The first clinical study to evaluate human iPSC-derived cells was initiated in 2014. The study used human iPSC-derived retinal pigment epithelial (RPE) cells to treat macular degeneration 4 , and the treatment was reported to improve the patient's vision 5 . Although the trial was subsequently put on hold owing to the identification of two genetic variants in the iPSCs of a second patient, it is anticipated to resume 6 . Clearly, human iPSC technology holds great promise for human disease modelling, drug discovery and stem cell-based therapy, and this potential is only beginning to be realized. In this article, we provide an overview of the progress in each of the main applications of iPSCs in the decade since the discovery of the technology. We present key illustrative examples, discuss remaining limitations and approaches to address them, and highlight emerging opportunities.
iPSC-based disease modelling
Identifying the pathological mechanisms underlying human diseases has a key role in discovering novel therapeutic strategies. Animal models have provided valuable tools for modelling human diseases, enabling the identification of pathological mechanisms at distinct developmental stages and in specific cell types in an in vivo setting. Moreover, in mice, it is possible to develop in vitro iPSC-based disease models and the 
Regenerative medicine
A therapeutic approach in which damaged tissues or organs are replaced by stimulating self-repair or using in vitro-cultured tissues or organs derived from cells, presumably stem cells, of a patient or a donor.
Gene editing
Genetic engineering in which DNA is modified by engineered nucleases. A relevant example is to make isogenic induced pluripotent stem cell lines using gene editing.
CRIPSR-Cas9 technology
A highly popular gene editing tool based on a bacterial clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) nuclease from Streptococcus pyogenes. This technology has gained wide usage in gene editing because of its simplicity in design and ease of use.
Precision medicine
A model that aims to offer medical treatment tailored to individual patients.
corresponding in vivo models in parallel. Comparing the phenotypes observed with corresponding in vitro and in vivo mouse models could provide a better understanding of the strength and limitations of in vitro human iPSC-based models.
However, substantial species differences could prevent the recapitulation of full human disease phenotypes in animals such as mice, which are the most commonly used animal models. For example, although many transgenic mouse models have been created for Alzheimer disease, none has captured the entire spectrum of the human disease pathology, including considerable neuronal loss 7, 8 . This lack of disease recapitulation is probably due to fundamental species differences between mouse and human neural cells. Thus, there is an urgent need to establish human disease modelling platforms to complement studies that use animal models for biomedical research.
Disease modelling using primary patient-derived cells is helpful for studying the aetiology of human diseases and for developing therapeutic strategies for these diseases. However, the lack of expandable sources of primary cells from patients, particularly hard-to-access cells such as brain cells and heart cells, is a critical limitation. Human iPSCs are therefore an attractive alternative because of the ease with which human diseases (particularly those with defined genetic causes) could, in principle, be modelled using iPSCs that are derived from easily accessible cell types, such as skin fibroblasts and blood cells, from diverse patients. Because of their intrinsic properties of self-renewal and potential to differentiate into nearly any cell type in the body, patient-specific iPSCs could provide large quantities of disease-relevant cells and a variety of different cell types that were previously inaccessible, such as neurons and cardiomyocytes. Furthermore, because iPSCs can be derived from the relevant patients themselves, they could enable personalized disease modelling that would be a central part of precision medicine.
Both human ESCs and iPSCs have been used for modelling human genetic diseases. The earlier models were developed using ESCs 9 , but, following the advent of human iPSC technology, human iPSCs have become the preferred option because of their availability and their lack of potential ethical concerns associated with human ESCs. Human iPSCs are highly similar to human ESCs. Both types of cells express human pluripotent factors and ESC surface markers, and exhibit the developmental potential to differentiate into three germ layers 2, 3 . Residual epigenetic memory of somatic cells could occur in iPSCs [10] [11] [12] , which may affect the differentiation potential of these cells 13 . Although the persistence of epigenetic memory of parental cells has been reported in iPSCs [10] [11] [12] , similar phenotypes have been reported in disease modelling using human ESCs and iPSCs in most cases 13 , supporting the effectiveness of disease modelling using patient-derived iPSCs.
Disease modelling using human iPSCs begins with the process of deriving iPSCs containing the diseasecausing mutation (or mutations) (FIG. 1) . These cells are then differentiated into disease-relevant cell types. The resultant cells are used to reveal disease aetiology and to identify pathological mechanisms. In early studies of iPSC-based disease modelling, iPSCs derived from non-disease-affected individuals were used as controls for patient-derived iPSCs. However, similarly to other cells, iPSCs exhibit line-to-line variations, which complicates data interpretation because one has to distinguish the line-to-line variations from the true disease-relevant phenotypes.
Rapidly developing genome editing technologies now enable the introduction of genetic changes into iPSCs in a site-specific manner, including correction of disease-causing gene mutations in patient-derived iPSCs and introduction of specific mutations into non-disease affected wild-type iPSCs. These approaches enable the generation of genetically matched, isogenic iPSC lines with the introduced mutation as the sole variable, ensuring the reliable identification of the true pathology while avoiding the confusion with any disparities in genetic background or epiphenomena resulting from possible line-to-line variations. Isogenic iPSC controls will be particularly important when modelling sporadic or polygenic diseases, in which phenotypic differences are anticipated to be small 14 
.
The development of programmable site-specific nucleases, including zinc-finger nucleases (ZFN) 15, 16 , transcription activator-like effector nucleases (TALENs) [17] [18] [19] and the CRISPR-Cas9 system [20] [21] [22] [23] (TABLE 1) , has substantially improved gene editing efficiency in human ESCs and iPSCs by inducing DNA double-stranded breaks at the site of gene modification. The CRISPR-Cas9 technology in particular has attracted much attention and gained wide usage in gene editing of human ESCs and iPSCs owing to its simplicity in design and ease of use. This gene editing technology enables researchers to introduce disease-causing mutations into wildtype iPSCs and to eliminate such mutations in patient iPSCs to create isogenic controls for iPSC-based disease modelling (FIG. 1) .
Box 1 | Evolution of human iPSC technology
Since its beginning in 2006, induced pluripotent stem cell (iPSC) technology has evolved rapidly. Because iPSCs were initially generated by introducing reprogramming factors via integrating viral vectors, such as retroviral or lentiviral vectors, there was a concern about the clinical application of these iPSCs owing to the potential for insertional mutagenesis caused by the integration of transgenes into the genome of host cells 204 .
To make iPSCs more clinically applicable, various non-integrating methods have been developed to circumvent the risk of insertional mutagenesis and genetic alterations associated with retroviral and lentiviral transduction-mediated introduction of reprogramming factors 205 . These non-integrating methods include reprogramming using episomal DNAs 206, 207 , adenovirus 208 , Sendai virus 209 , PiggyBac transposons 210 , minicircles 211 , recombinant proteins 212 , synthetically modified mRNAs 213 , microRNAs 214, 215 and small molecules 216 , although the small-molecule approach is not yet applicable to human iPSC derivation.
Among these approaches, episomal DNAs, synthetic mRNAs and Sendai virus are commonly applied to derive integration-free iPSCs owing to their relative simplicity and high efficiency 185 . The use of nonviral methods or non-integrating viruses could avoid genomic insertions, thus reducing associated risks when human iPSCs are used for clinical applications. 
Exome sequencing
A technology that determines the sequence of all expressed genes in a genome. It is also called whole exome sequencing (WES).
Targeted deep sequencing
An approach that determines the sequence at regions of interest using next-generation sequencing technology.
Direct conversion
A technology that enables one type of somatic cell to be reprogrammed into another type of somatic cell.
However, a major challenge in applications using the CRISPR-Cas9 technology is the possibility of off-target effects. Nevertheless, although relatively high levels of off-target gene modifications by CRISPR-Cas9 have been described in cancer cell lines 24 , recent reports from multiple laboratories using whole genome sequencing (WGS) indicate that off-target gene modifications are rare in normal human cells, including human iPSCs and ESCs [25] [26] [27] [28] [29] . WGS using genomic DNAs isolated from the original iPSCs and corresponding gene edited iPSCs, coupled with comprehensive bioinformatics analysis 25, [27] [28] [29] , is useful for detecting off-target effects such as single-nucleotide variants (SNVs) and insertions or deletions (indels), particularly for cells that will be used for clinical applications. Currently, WGS is expensive, but it is anticipated that the costs will fall as the technology develops. Alternative approaches for detecting off-target effects include exome sequencing 30 and targeted deep sequencing 29 . For targeted deep sequencing, one can search for potential off-target sites that are different from the on-target sites in the human genome using Cas-OFFinder 31 , an algorithm for identifying off-target sites, including off-target SNVs or indels.
Gene editing tools are also being continuously improved and refined, which may help to address the issue of off-target effects. The original CRISPR-Cas9 technology edits a genomic locus by inducing DNA double-stranded breaks using a single guide RNAdirected wild-type Cas9 nuclease. The nickase version of Cas9 (D10A mutant) directed by paired guide RNAs and the engineered Cas9 nuclease variants with enhanced specificity (eSpCas9) are now increasingly being used for genome editing [32] [33] [34] because both have demonstrated substantially reduced off-target effects while retaining rigorous on-target cleavage 34, 35 . Furthermore, catalytically dead Cas9 (dCas9) fused with a transcriptional activator or suppressor can be used to modulate transcription of endogenous genes (so-called CRISPRi or CRISPRa) or image genomic loci by fusing with a fluorescent protein [32] [33] [34] 36 . Modifications of the CRISPR-Cas9 system also enable the explicit introduction of DNA sequence changes in a precise monoallelic or biallelic manner with high efficiency 37 . A recent development in base editing takes advantage of the fusion of CRISPRCas9 and a cytidine deaminase enzyme to enable direct conversion of cytidine to uridine without the need of a DNA double-stranded break 38 . This new approach enhances gene editing efficiency and will further facilitate gene editing in human ESCs and iPSCs.
iPSC-based disease modelling is widely used for studying disorders caused by a single gene mutation (monogenic disorders) that have an early onset 39, 40 . This approach is ideally suited to such disorders because iPSCs can be easily derived from patients and differentiated into disease-relevant cells, such as neurons. Furthermore, given the relative immaturity of cells differentiated from iPSCs 41 , there is greater confidence that the phenotypes of cells differentiated from iPSCs provide a good model for diseases with an early onset versus late onset, for which cellular ageing may be important in disease pathology 41 . For example, neurons differentiated from patient-derived iPSCs were used to model spinal muscular atrophy (SMA), an early-onset disease caused by mutations in survival motor neuron 1 (SMN1) 39 . Mutations in SMN1 lead to the degeneration of motor neurons and subsequent muscular atrophy. Patients with type 1 SMA usually show symptoms at 6 months from birth, with a rapid disease progression that is fatal by the age of 2 years 42 . In an initial iPSC-based disease modelling study 39 , iPSCs derived from fibroblasts of a patient with type 1 SMA were differentiated into a disease-relevant cell type, motor neurons. The motor neurons differentiated from the patient-derived iPSCs exhibited reduced survival compared with that of motor neurons derived from an unaffected control. Moreover, treatment of the patient-derived iPSCs with valproic acid and tobramycin (two compounds known to induce the expression of SMN1) led to increased levels of SMN1 protein and SMN1 protein-containing 'gems' (REF. 39 ). This study provided proof of principle that patient-derived iPSCs can be used to model early-onset genetic diseases and serve as potential drug-screening platforms.
Modelling diseases that have a late onset is more challenging because cells differentiated from human iPSCs in general exhibit fetal-like properties 41 . However, induced cellular ageing has been used to aid in the successful modelling of late-onset diseases [43] [44] [45] [46] . One way to induce ageing in cells differentiated from human iPSCs is to treat these cells with cellular stressors: for example, with compounds such as MG-132 and pyraclostrobin, which target mitochondrial function or protein degradation 43, 44, 46, 47 . Another way to induce cellular ageing is to ectopically express gene products, such as progerin, that induce premature ageing 45 . However, whether cellular stressors or progerin expression can elicit cellular ageing through a mechanism that is similar to normal ageing remains to be determined 41 . Moreover, recent studies have indicated that cellular maturation and ageing may be distinct events 41, 48 . It remains unclear whether the cellular ageing inducers can promote both cellular maturation and ageing, as opposed to triggering cellular ageing in immature cells 48 . Alternatively, the direct reprogramming approach, which involves the direct conversion of human fibroblasts into other lineage-specific cells, such as neurons, does not erase cellular ageing markers 49 . Indeed, neurons derived from aged fibroblasts through direct reprogramming maintain cellular age 50 , therefore offering an alternative cellular model to study age-related disorders. It is worth noting that there has also been success in promoting cellular maturation, such as by using improved formulations of cultured medium 51 or using a neuron-astrocyte co-culture system 52, 53 . iPSCs also offer a new way to study sporadic diseases (the causes of which have not been identified in patients' family histories or genetic mutations), which is important as the majority of patients with many diseases have sporadic forms of the disease. For example, in Alzheimer disease, 95% of patients fall under the sporadic category. Interestingly, an analysis of iPSC-derived nerve cells from patients with sporadic Alzheimer disease identified several sporadic cases that exhibited the same phenotypes as familial Alzheimer disease caused by a specific gene mutation 54 . This finding indicated the possibility of re-classifying the sporadic condition using iPSCs. However, modelling sporadic diseases using iPSCs is generally more difficult than modelling monogenic disorders because the phenotypic changes in such diseases are often thought to be induced by multiple small-effect genetic risk variants in combination with environmental factors. Although iPSCs derived from patients with sporadic diseases would contain disease-relevant risk variants, using iPSCs to model such diseases is complicated by line-to-line variations in genetic and epigenetic background. Such variations are more problematic for modelling sporadic diseases because the phenotypes of the sporadic disease iPSC-derived cells are anticipated to be subtler than for those derived from monogenic disease iPSCs.
Thus, a key question for human iPSC-based modelling of sporadic diseases is how to generate paired isogenic cell lines that only differ at relevant risk variants 14 . The ability to generate genetically controlled isogenic iPSC lines in which specific disease-associated genetic risk variants are the sole variable using CRISPRCas9 technology can create a well-controlled system. Recently, this approach was used to generate isogenic iPSC lines that differ at a Parkinson disease-associated risk variant, which in combination with an allelespecific assay, enabled the robust dissection of this genetic risk variant 55 . This experimental strategy could be applied to studying genetic risk factors associated with other diseases.
So far, many diseases have been studied using a single disease-relevant cell type derived from iPSCs. For example, iPSC-derived neurons have been used to model Alzheimer disease 54,56-68 (TABLE 2) and Parkinson disease [43] [44] [45] 55, [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] (TABLE 3) . However, more than one cell type may be required to effectively model some diseases. Indeed, comparable efforts have been devoted to model schizophrenia using patient iPSC-derived neurons [85] [86] [87] and neural progenitor cells [88] [89] [90] [91] [92] . To better recapitulate disease phenotypes, the co-culture of more than one cell type may also be needed to study the interaction of different cell types. For example, astrocyte-neuron co-cultures have been used to model the pathology of amyotrophic CORRECT, consecutive re-guide or re-Cas steps to erase CRISPR-Cas9-blocked targets; DSBs, double-stranded breaks; eSpCas9, enhanced specificity Streptococcus pyogenes (Sp) Cas9; HDR, homology-directed repair; indels, insertions or deletions; NHEJ, non-homologous end joining; sgRNA, small guide RNA; TALEN, transcription activator-like effector (TALE) nucleases; ZFN, zinc-finger nuclease.
Organoids
In vitro cultured 3D organ buds that resemble the cellular organization and structure of human organs, but are more primitive and at a smaller scale than endogenous organs.
lateral sclerosis (ALS) [93] [94] [95] [96] . The co -culture system enabled the investigation of non-cell-autonomous aspects of disease pathology, which would otherwise be impossible with single cell types such as neurons. Moreover, these studies facilitated the identification of astrocytes as a critical cellular component that contributes to motor neuron degeneration in ALS and provided a drug screening platform for ALS using patient iPSC-derived astrocytes [93] [94] [95] [96] .
The interactions between different cell types can be better modelled using 3D organoids. Organoids have been generated for multiple organs, including the brain, retina, intestine, kidney, liver, lung and stomach, using both tissue stem cells and pluripotent stem cells from mice and humans 97 . Human iPSC-derived organoids have been developed for various applications owing to their resemblance to endogenous cell organizations and organ structures, and are particularly useful because they enable the study of cell-cell interactions in a cellular context that mimics human physiology and development. Indeed, 3D organoids have been used to model human organ development and diseases, to test therapeutic compounds and in cell transplantation [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] (TABLE 4). Multiple cell types that are physiologically relevant can be generated in organoids following a spatiotemporal order. Moreover, cells generated in organoids can be functionally more mature than cells derived using directed differentiation protocols owing to the interaction of different cell types, such as neurons and astrocytes, in the 3D structure. Therefore, 3D organoids facilitate the dissection of disease pathology in a developmentally relevant spatiotemporal context and have the potential to model a drug response at the level of an organ rather than at the level of individual cells.
Although 3D organoids provide highly promising tools for iPSC-based disease modelling, the organoid technology has limitations. One challenge is to create an organoid platform with increased efficiency and reproducibility compared with traditional 2D cultures 115 . The recent application of miniaturized spinning bioreactors with 3D design has enabled the generation of forebrain organoids with high reproducibility 110 . The development of a more standardized organoid culture medium, together with a more defined extracellular matrix, would further facilitate the generation of a highly reproducible organoid system that is more applicable for accurate disease modelling, drug discovery and therapeutic development 116 . Another challenge is the lack of vascularization in the current organoid system 97 . Accordingly, organoids exhibit limited growth and maturation owing to the lack of continuous nutrient supply. Spinning bioreactors and shaking culture platforms are able to provide better nutrient supply and improve the growth of organoids 110, 117 . In addition, co-culture with endothelial cells has enabled the generation of vascular-like network in organoids 99 . Moreover, transplantation of in vitro-generated human organoids into relevant sites of animal hosts facilitates vascularization and maturation of organoids. This transplantation approach may be applied when organoids with increased size and improved maturation are needed for the study.
iPSC-based drug discovery Screening for efficacy. Many drug screens are based on targets that are considered to be relevant to the disease mechanisms. However, the low success rates of compounds originating from target-based screening have led to greater interest in phenotypic screening 118 . This revival in phenotypic screening has been aided by the discovery of iPSCs for numerous reasons, including the scalability of iPSC production, which facilitates assay development. Moreover, the pluripotency of iPSCs means that these cells can be differentiated into multiple disease-relevant cell types, especially those that are otherwise hard to access, such as neurons 119 . Patient-derived iPSC models make it possible to recapitulate disease phenotypes and pathologies in a culture dish. Cells differentiated from patient-derived iPSCs could present molecular and cellular phenotypes. Whether the phenotype that is selected as a readout for a drug screen is truly relevant to the disease can be confirmed by a gene editing approach if the gene responsible for the disease phenotypes is known, and can be further validated in patient samples and/or animal models 120 . In addition to phenotypic screening, iPSCs can be used for target-based screening. Using human iPSC models, many drug screens have been conducted, and potential drug candidates have been identified using either phenotypic or target-based screening.
To obtain target cells with high purity on a large scale, purification and enrichment technologies using specific cell-surface markers 121, 122 , cell-specific promoters 123 and microRNAs 124 have been established. In the first report of a large-scale drug screen using an iPSC-based disease model, neural crest precursors for autonomic neurons were sorted and purified from iPSCs derived from patients with familial dysautonomia, a monogenic early-onset disease that is characterized by degeneration of neurons in the sensory and autonomic nervous systems 121 . This disease is caused by mutations in IκB kinase complex-associated protein (IKBKAP), which results in a splicing defect and the production of a dysfunctional truncated protein. The drug screen was conducted using 6,912 compounds, and a compound known as SKF-86466 improved disease-specific aberrant splicing. Interestingly, SKF-86466 was not effective in non-target cells, including iPSCs, fibroblasts and lymphocytes. These results illustrate the advantage of iPSC-based drug screening to explore cell type-specific pathogenesis.
Burkhardt et al. 125 performed disease modelling and drug screening using iPSCs derived from patients with sporadic ALS. The authors identified de novo aggregation of TAR DNA-binding protein 43 (TDP43) in motor neurons of these patients, and thus used TDP43 aggregation as a readout for a high-content drug screen to identify compounds that reduced TDP43 aggregation 125 . The same research team also made effective use of a patient-derived iPSC model of Alzheimer disease 126 . The authors identified a disease-relevant protein, extracellular tau (eTau), in the conditioned medium of cortical neurons derived from the iPSCs of a patient with Alzheimer disease, and then generated a therapeutic antibody against eTau 126 . This disease-relevant protein would not have been discovered without using the human iPSC model. eTau causes neuronal hyperactivity and increases amyloid-β production. Using human iPSC models as a tool to identify disease-relevant targets could be a crucial component for future drug development. Naryshkin et al. 127 found that a patient-derived iPSC model of SMA could be used to validate human-and disease-specific drug responsiveness after initial screening using a HEK293 cell line 127 . These compounds were then validated in patient-specific fibroblasts and in motor neurons differentiated from patient-derived iPSCs that served as a patient-specific and disease-relevant cellular model 127 . Finally, the hit compound was evaluated in a mouse model for in vivo activity 127 . This drug discovery approach included a patient-derived iPSC model as one of the validation steps by taking advantage of the patient-specific and disease-relevant properties of motor neurons derived from patient iPSCs.
Overall, iPSC-based drug screening has been used to evaluate more than 1,000 compounds for several diseases 121, 125, 128, 129 (TABLE 5) , and several clinical candidates have been identified 126, 127, 130 (TABLE 6) . However, these studies require considerable time (several weeks or more) to differentiate iPSCs into disease-relevant cell types. Although this length of time may not seem long for phenotypic screening, a shorter differentiation period is preferable to avoid variation in cell quality. Therefore, faster and more stable differentiation methods that result in higher maturity and purity are being sought. An alternative approach is to perform drug screening using cells derived from direct conversion 131, 132 . Direct conversion forces the target somatic cells (for example, fibroblasts) to express cell-specific transcription factors and to reprogramme one somatic cell state to another somatic cell state without passing through the iPSC state 49, 132 . Direct conversion has been used to reprogramme myocardial cells, liver cells, neural cells or other types of somatic cells from a different type of somatic cell, such as fibroblasts. As noted above, an advantage of direct conversion is that authentic human neurons reflecting important aspects of cellular ageing can be generated 50 . However, the non-renewable source of cells provided by this approach may not be applicable for large-scale drug screening. The forced expression of transcription factors also offers the potential to differentiate patient iPSCs more rapidly. In a recent study, the forced expression of myogenic differentiation 1 (MYOD1), a master regulator of skeletal muscle differentiation, was used to produce new cellular models of intractable muscle disease pathologies such as Miyoshi myopathy 133 and Duchenne-type muscular dystrophy 134 . An important point to consider in pathology research using iPSCs is the nature of the control group. For genetic disorders, a control group can be created by conducting 119 . iPSCs are also invaluable models in the case of sporadic diseases. In these cases, because no causal mutation is known, the nature of a control group is difficult to establish; however, disease-relevant single-nucleotide polymorphisms (SNPs) can be considered instead 65 . As described in the "Perspectives" section below, for future drug screening, sporadic disease iPSCs should facilitate the investigation of whether the disease is caused by genetic factors such as SNPs, somatic mutations, mosaicism or epigenetic factors. These developments could further open the door to personalized drug screening using iPSCs 135 . Another application of disease-specific iPSCs is in drug repositioning, in which existing drugs already approved for specific diseases are tested to find new applications in other diseases. For example, a human iPSC model derived from patients with achondroplasia with mutations in fibroblast growth factor receptor 3 (FGFR3) showed that patient-derived iPSCs did not differentiate well into cartilage tissue 136 . Using this model, a screen for molecules that rescued chondrogenically differentiated iPSCs from the defective cartilage phenotype identified several statins, which are approved drugs for cardiovascular disease. The same study found that statins could promote the growth of shortened limbs in a mouse model of FGFR3-linked disease. These results indicate that statins may be repositioned as candidate drugs for achondroplasia 136 . As another example of drug repositioning, the anti-epileptic drug ezogabine demonstrated efficacy in an iPSC model of the motor neuron disease ALS and is now undergoing a clinical trial 137 . In this study, the authors showed the effect of ezogabine on an iPSC model derived from both patients with ALS harbouring mutations in the superoxide dismutase 1 (SOD1) gene and patients with ALS harbouring mutations in other genes linked to ALS, such as C9ORF72 and FUS. It has also been demonstrated that iPSC motor neurons derived from patients with ALS initially exhibit a hyper-excitable state followed by a decrease in excitability 138 . This finding suggests that early intervention with ezogabine may be required for the treatment of ALS. The observation of a similar drug response in different patient groups enabled the generalization of drug responsiveness across ALS types. Drug discovery using iPSCs derived from multiple genetic forms of a disease is of great value because it allows testing of the drug responsiveness in a broad patient population. By contrast, it is challenging to analyse the effect of a drug in multiple mouse models simultaneously.
Screening for toxicity. The development of new drugs is enormously costly. The high costs are mostly because of failures, particularly those in late-stage clinical trials, which are in turn partially due to unanticipated side effects 139, 140 . Many unpredicted adverse effects of new candidate drugs can occur, with cardiac and liver toxicity being of particular concern. Consequently, there is considerable interest in developing approaches that could more effectively predict the likelihood of candidate drugs to cause serious side effects, thereby enabling the selection of candidates that are less likely to fail owing to toxicity in late-stage trials.
Lethal arrhythmias with a QT prolongation account for 21% of total cardiac toxicities 141 . QT prolongation is an adverse effect related to human ether-a-go-go-related gene (hERG; also known as KCNH2) channels. Cardiac safety testing has primarily depended on the hERG assay because blocking the hERG current is considered to be associated with the deadly ventricular arrhythmia named torsades de pointes. However, it has been discovered that 40-60% of drugs that inhibit hERG channel currents do not cause QT prolongation 142, 143 . These false-positive results from the hERG assay may have hindered the development of promising drugs. Various preclinical strategies have been proposed to detect drug-induced electrophysiological cardiotoxicity, including using in vitro human ion channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes 144 . Recent efforts have shown that multi-electrode arrays using human iPSC-derived cardiomyocytes may offer a reliable, cost-effective surrogate for preclinical in vitro testing 145 that could be used to assess pro-arrhythmic risk 146 . For hepatotoxicity, hepatocyte cell lines or human primary hepatocytes are widely used. However, these models also have limitations, including cell resources, loss of function due to freezing-thawing and lot-to-lot variation. Recently, human ESC-and iPSC-derived hepatic cells were generated that express functional molecules such as cytochrome P450 3A4 (CYP3A4), can take up indocyanine green 147 and respond to known hepatotoxic drugs 148 . Functional 3D liver organ buds have also been reported, which may result in better drug screening 99 . Finally, regarding the nervous system, a platform that assesses adverse drug effects using pluripotent stem cells is currently being developed. To conduct such an assessment, the analysis of gene expression alterations of cells in the nervous system, such as neuronal cells, mesenchymal stem cells and vascular endothelial cells derived from human ESCs in a culture dish, has been proposed 149 .
Clinical applications using human iPSC products
The potential of regenerative medicine based on the use of stem cells to promote endogenous regenerative processes or to replace damaged tissues after cellular transplantation has attracted considerable interest. Since the discovery of human ESCs in 1998 (REF. 150 ) and of human iPSCs in 2007 (REFS 2,3) , the stem cell research community has continued to identify more suitable sources for exploring cell therapy and endogenous repair in humans. A general approach to develop iPSCbased cell therapy products is summarized in FIG. 2 . Of the 13 ongoing clinical trials evaluating stem cell therapy products, 8 are for ESC-and 1 is for iPSC-derived RPE cells to treat macular degeneration, which causes the progressive deterioration of light-sensing photoreceptors in the eye (see ClinicalTrials.gov) 151 . In 2014, the first clinical study using human iPSC products was initiated by transplanting RPE sheets derived from the patient's own iPSCs. The therapy resulted in positive results, stopping macular degeneration and improving the vision of the patient. Although the trial was subsequently put on hold owing to mutations observed in a second patient's iPSCs 4 , it is anticipated to resume 6 . In addition, a recent study has demonstrated the feasibility of transplanting human ESC-derived cardiac progenitor cells embedded in a fibrin scaffold to patients with severe heart failure 152 . However, there are several obstacles associated with iPSC-based therapy that will need to be addressed before routine clinical applications can begin 153 . One concern is the risk of tumorigenicity from ESCs and iPSCs 154 . Because pluripotent cells are maintained in culture for prolonged periods of time, they can accumulate karyotypic abnormalities and copy number variants and lose heterozygosity 155 . Hence, before clinical use, iPSC-derived products need to be carefully screened for the lack of potentially risky genetic alterations 155 and rigorously tested to ensure their purity, quality and sterility. Increased knowledge of the basic biology of pluripotency induction and maintenance will also help in reducing the risk of mutation development and genetic instability associated with human iPSC derivation and maintenance.
Although the products differentiated from iPSCs have not been shown to generate teratomas, it is critical to ensure that the final product does not contain undifferentiated cells that have the potential to generate teratomas. Accordingly, improved protocols for differentiating human iPSCs into desired cell types with precise identity and cellular functions are needed. To this end, small-molecule inhibitors that have been shown to induce selective and complete cell death of undifferentiated human pluripotent stem cells without affecting their differentiated derivatives have been identified 156, 157 . Treatment of the iPSC-derived cellular product with these inhibitors may reduce the potential tumorigenicity. Another potential solution is to sort the iPSC-derived cells before transplantation through positive selection for desired cell types and negative selection against human ESC markers using fluorescence -activated cell sorting. Finally, the risk of tumorigenicity can be tested in animal models before transplant. However, this approach may not be applicable in patients with rapid disease progression owing to the long period of time associated with animal tests.
Compliance with good manufacturing practice is mandatory before human transplantation of cell therapies. Once cells are safely delivered, patients should ideally be monitored for the development of potential tumours and activation of the immune system 158 . One approach for tumour monitoring may be to assess the enhanced angiogenesis that often accompanies teratoma formation, Figure 2 | A schematic for human iPSC-based cell therapy. The development of human induced pluripotent stem cell (iPSC)-based cell therapies can be broken down into six steps. First, somatic cells are collected from affected patients and cultured. Second, the patient somatic cells are reprogrammed into iPSCs. Third, genome editing technology or a viral transduction method is used to genetically correct the patient-derived iPSCs. Fourth, the corrected iPSCs are differentiated into desired cell types to serve as genetically matched healthy donor cells. Fifth, quality control tests for cell identity, purity, activity and safety are performed. Finally, the genetically matched healthy cells are transplanted into patients for cell therapy.
Autologous
Of the same individual.
Allogeneic
Of genetically different individuals from the same species.
which can be detected using the 64 Cu-labelled cyclic arginine-glycine-aspartic acid tetramer ( 64 Cu-DOTA-RGD4) radiotracer with positron-emission tomography imaging 159 . Another approach may be to use a combination of serum biomarkers (for example, carcinoembryonic antigen, α-fetoprotein or human chorionic gonadotropin) and magnetic resonance imaging screening, as described recently 160 . However, it is worth noting that these approaches would be mostly useful at the preclinical stage, especially if they are already part of the imaging procedure required for evaluating an end point. Their feasibility and necessity for future human trials remain to be determined.
The lack of an effective method of inducing immune tolerance is a major roadblock for human ESC-based therapies. ESCs were once considered to be immune privileged owing to the low levels of expression of major histocompatibility complex (MHC) class I, MHC class II and co-stimulatory molecules 161 . Although undifferentiated ESCs might be immune-privileged, their differentiated derivatives can trigger cellular and humoral immune responses 162 . By contrast, autologous iPSCs might avoid the high cost and serious side effects associated with lifelong immunosuppression required for allogeneic cell transplantation 163 . Despite some controversy regarding the immunogenicity of undifferentiated iPSCs 164 , recent studies have demonstrated that the differentiation of iPSCs could result in loss of immunogenicity [165] [166] [167] . The application of cells derived from individual patients' own iPSCs or iPSCs from matched donors may become a cornerstone of precision medicine and has the important advantage that there should be no need for long-term immune suppression to preserve the transplanted cells. Indeed, the first iPSC clinical trial used RPEs from autologous iPSCs derived from the patient. Using autologous iPSC products for personalized cell therapy seems to be ideal for orphan diseases, as massive cell banking is not required. However, for more common diseases, particularly acute common diseases such as cerebrovascular accident or myocardial infarction, autologous iPSC therapy may not be practical for large numbers of patients given the high cost and lengthy period of time needed for careful validation of each cell line. For these reasons, the second phase of the iPSC RPE trial in Japan will be using allogeneic products 168 . The allogeneic iPSC approach could also bring down the cost for iPSC-based cell therapy. Excluding the high start-up cost, each iPSC line costs ~US$10,000-20,000 to produce 169 . Meeting current good manufacturing practice requirements substantially increases this cost 170 . Costs are even higher, by approximately $800,000 (REF. 169) , to generate an iPSC-derived tissue product suitable for clinical use (for example, differentiation of iPSC neuronal cells for cerebrovascular accident, iPSC cardiomyocytes for myocardial infarction or iPSC RPE cells for macular degeneration). Banking iPSCs for allogeneic transplant has the potential to reduce costs because one production may be used for multiple patients. To facilitate allogeneic transplant, the effectiveness of conventional immunosuppressive protocols and newer regimens of co-stimulatory blockers for inducing immunotolerance will need to be improved in preclinical and clinical settings 171, 172 . Moreover, understanding how pluripotent stem cells interact with the immune system and why they may be more tolerance-inducing than other transplanted cells may lead to the identification of new immunosuppressive mechanisms and strategies 163 . Furthermore, transplantation into immune-privileged sites may serve as a possible strategy to overcome immune rejection. Incorporating recent advances in genome editing strategies to create universally accepted donor cells could be another alternative approach 173 . The combination of the human iPSC platform with the recently developed gene editing and 3D organoid technologies could make human iPSCs an even more powerful cellular resource for stem cell-based cell therapy development. As a proof of principle, mouse iPSCs corrected through gene editing have been used to generate haematopoietic progenitors to successfully treat sickle cell anaemia in a mouse model 174 . Furthermore, the integration of genetically corrected human iPSCs with 3D organoids could enable tissues to be generated as sources for organ replacement therapies 97 . Indeed, human iPSC-derived liver organoids have been shown to successfully generate functional human liver-like tissues in transplanted mice in a proof-of-principle study 99 . However, there are still challenges to overcome for such approaches to become applicable in human cell therapy. For example, the potential off-target effects associated with gene editing need to be addressed, as do the limitations of organoids, as described in the section "iPSC-based disease modelling".
Perspectives
The discovery of iPSCs has provided a revolutionary new research platform for the study of diseases. In the 10 years since the first iPSC report, great progress has been made in investigating disease mechanisms and potential treatments by combining human iPSCs with other new technologies. However, several important issues remain to be addressed.
iPSC clones show variations in differentiation efficiency, including clones derived from the same person 119 . These variations are important to consider when selecting control groups for disease modelling studies. Applying CRISPR-Cas9 technology may help to address this issue, as discussed above. Multiple reports have now shown that gene correction of an iPSC mutation improves the disease phenotype of differentiated cells [175] [176] [177] [178] . In addition to correcting gene mutations in disease iPSCs, researchers have successfully introduced gene mutations into healthy iPSCs 87, 88 . However, several challenges for the combination of CRISPR-Cas9 technology with iPSC technology remain, including the off-target effects of CRISPR-Cas9 editing, the high cost of assaying for them and the limited application of gene editing to genetic diseases with unknown disease-causing mutations or risk variants 14 . Nevertheless, the potential of this combination to dissect disease mechanisms and to develop new cell therapies is high. Moreover, CRISPR-Cas9 or CRISPRi-based genome-wide genetic screening 179, 180 
in human iPSCs

MicroRNA switch
A biotechnology that turns a gene on or off depending on the microRNA (or microRNAs) inside the cell.
Disease repositioning
Redefinition of a disease based on disease induced pluripotent stem cell-based phenotypes to identify common and new therapeutic approaches across diseases.
could open a new avenue for understanding basic biological mechanisms underlying human iPSC pluripotency, maintenance and differentiation. In contrast to mouse ESCs and iPSCs that represent the 'naive' state and are homogeneous, human ESCs and iPSCs represent the 'primed' state and are heterogeneous in both cell population and differentiation potential 181, 182 . Moreover, the reprogramming process can result in both fully reprogrammed iPSCs and partially reprogrammed cells, which may have different differentiation potential 183, 184 . Therefore, human iPSCs need to be carefully selected and thoroughly characterized for their pluripotency before clinical applications 185 . Further basic research on reprogramming mechanisms may help researchers to develop methods that facilitate the generation of a standardized human iPSC state, which would lead to reduced technical variability and enable the identification of true biological phenotypes. In addition to clonal variation in iPSC differentiation efficiency, another obstacle for disease modelling is line-to-line variations in the maturation of differentiated cells. The acquisition of mature cells requires improved culture conditions and the use of fate conversion with gene regulation 119 . A recent technology, the microRNA switch 124 , is anticipated to increase the maturation quality of iPSC-differentiated cells and to reduce clonal variation.
In conventional disease-modelling studies, cells are seeded in a 2D plane. However, in vitro models with a 3D structure are closer to the physiological condition and thus may be better suited for the study of disease pathology. Using disease-specific iPSCs, technologies for inducing the differentiation of several 3D structures, including those similar to the cortex, optic cup, Rathke's pouch, cerebellum and hippocampus, have been reported [186] [187] [188] [189] [190] [191] . By taking advantage of the dynamic patterning and structural self-formation of complex organ buds, the construction of 3D structures and their corresponding networks has become a reality. Such a strategy is already being used in disease modelling for brain abnormalities 117 and mental illness 108 . Similarly to the self-organization of ectodermal tissue structures, endodermal tissue formation in 3D stem cell culture 99 has been developed and applied to gastrointestinal disease modelling 192 . Physiological interactions among complex tissues from different lineages but with the same genetic background, such as the blood-brain barrier 193 or the immune system 194, 195 within the organoid, could provide new insights into normal physiology and diseases 196, 197 . Although several limitations exist in current 3D technology 198, 199 , as detailed in the "iPSC-based disease modelling" section, combining disease-specific iPSCs with 3D technology enables the examination of spatio temporal cellular interactions that could reveal the physiological disease status, thus providing an unprecedented drug-screening platform and offering a new option for tissue-replacement therapy. However, transplantation of human stem cell-derived organoids into animals to generate human tissues or organs may bring new issues in biomedical ethics that warrant further attention 200 , such as the potential of transplanted human stem cells to mix with host cells and to develop in the nervous system and germ lines of host animals.
iPSCs also provide a new way to study sporadic diseases. Before the development of iPSC technology, it was impossible to analyse sporadic diseases in cellular models, but now several studies have successfully modelled sporadic neurological diseases 54, 57, 65, 73, 85, 108, 125, 135, 201, 202 . It has been hypothesized that the pathological mechanisms of sporadic diseases might be the same as familial ones. However, sporadic and familial diseases have marked differences, such as the age of onset and severity, as well as the pathology.
iPSC models suggest that even if the effect of each individual genetic risk is small, the combined effect may initiate and accelerate the development of the pathology of sporadic diseases. In addition, even if SNP genotyping only indicates a small risk factor, it could be an important one, and modelling the pathological phenotype with iPSC technology could lead to a re-classification of sporadic diseases. Such re-classifications could have important implications for drug development. iPSC modelling has the potential to identify drug-responsive patient subgroups, including those with sporadic diseases, which should improve the quality of clinical trials 119 . A large cohort analysis with medical records and genome information combined with patient iPSCs is also anticipated; thus, iPSC-derived cells could provide a much more precise analysis of the individual genes and proteins involved in the disease.
Accumulating information from disease iPSC research, in combination with patients' personalized clinical experience, will aid disease repositioning, in which diseases are defined not by clinical but by cellular phenotypes. If an analysis of the cellular phenotypes of in vitro iPSC models of clinically different diseases indicates that the phenotype is identical or similar, then a treatment that is effective in one condition may be effective in the others. For example, an iPSC model of bipolar disorder identified hyperexcitable neuronal cells 201 . Similar hyperexcitability was found in iPSC-derived motor neurons from a patient with ALS 203 . Therefore, the same therapeutic agent may be effective for these clinically disparate but cellularly similar diseases. Accumulating data of cellular phenotypes of iPSC models from a cross-sectional variety of diseases may contribute to new stratifications and understanding of different diseases, which could also lead to new cross-sectional treatment approaches.
The development of iPSC technology has generated a powerful new way to both define and treat diseases. iPSCs represent a paradigm shift because they now allow us to directly observe and treat relevant patient cells. In particular, they have revealed new relationships between disease phenotypes and gene expression profiles, which have broadened and deepened our understanding of disease development in patients, particularly those with sporadic diseases. Progress with other technologies, such as CRISPR-Cas9, 3D organoids and microRNA switches, will further advance the already rapid pace of iPSCbased disease modelling and therapeutic development. 
